

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*Neither this announcement nor any copy thereof may be released into or distributed directly or indirectly in the United States or any other jurisdiction where such release or distribution might be unlawful.*

*This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities.*

*This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 (the “**U.S. Securities Act**”), and may not be offered or sold in the United States unless registered under the U.S. Securities Act or pursuant to an exemption from, or in a transaction not subject to, registration under the U.S. Securities Act. The Company has no intention to register under the U.S. Securities Act any of the securities referred to herein or to conduct a public offering of securities in the United States.*



**Genscript Biotech Corporation**

**金斯瑞生物科技股份有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock code: 1548)**

**COMPLETION OF  
SUBSCRIPTION OF SHARES UNDER  
TOP-UP PLACING AND SUBSCRIPTION**

Reference is made to the announcements of the Company dated 5 June 2018, 8 June 2018 and 13 June 2018 in relation to the Vendor Placing, the Subscription and the Wang Placing (collectively, the “**Announcements**”). Unless otherwise defined, capitalized terms used herein shall have the same meanings as those defined in the Announcements.

## COMPLETION OF SUBSCRIPTION OF SHARES UNDER TOP-UP PLACING AND SUBSCRIPTION

The Board is pleased to announce that the conditions of the Subscription have been fulfilled and the completion of the Subscription (the “**Subscription Completion**”) took place on 13 June 2018. An aggregate of 75,000,000 Subscription Shares have been allotted and issued to the Vendor at the Subscription Price of HK\$26.5 per Subscription Share.

The net proceeds from the Vendor Placing and the Subscription is approximately HK\$1,971,702,660.50 which is intended to be used for (i) building up CAR-T R&D and production facility in China, the U.S. and Europe; (ii) global team building for the Group’s talent program and CAR-T therapies, including regulatory, R&D, production and commercialization; (iii) building up the GMP manufactory facilities for plasmid and biologics products; and (iv) as general working capital purpose.

## EFFECTS ON THE SHAREHOLDING STRUCTURE OF THE COMPANY

Set out below is the shareholding structure of the Company immediately before and after the Subscription Completion:

Shareholder	Immediately after the Vendor Placing Completion and the Wang Placing Completion but before the Subscription Completion		Immediately after the Vendor Placing Completion, the Wang Placing Completion and the Subscription Completion	
	<i>Number of Shares</i>	<i>%</i>	<i>Number of Shares</i>	<i>%</i>
The Vendor ( <i>Note</i> )	812,402,024	46.20	887,402,024	48.41
Placees	90,000,000	5.12	90,000,000	4.91
Other public shareholders	855,883,771	48.68	855,883,771	46.68
Total	<u>1,758,285,795</u>	<u>100.00</u>	<u>1,833,285,795</u>	<u>100.00</u>

*Note:*

Immediately after the Vendor Placing Completion, the Wang Placing Completion and the Subscription Completion, the Vendor is interested in 887,402,024 Shares, representing approximately 48.41% of the existing issued share capital of the Company. The Vendor is owned as to approximately 28.83%, approximately 23.69%, approximately 22.36%, approximately 6.02%, approximately 1.04%, approximately 12.04% and approximately 6.02% by Zhang Fangliang (the Chairman and Chief Executive Officer and a director of the Company), Wang Luquan (a Director), Wu Yongmei, Ms. Wang, Mu Yingjun, 2017 Fangliang Zhang Family Trust, and 2017 Ye Wang Family Trust, respectively.

By Order of the Board  
**Genscript Biotech Corporation**  
**Dr. Zhang Fangliang**  
*Chairman and Chief Executive Officer*

Hong Kong, 14 June 2018

*As at the date of this announcement, our executive Directors are Dr. ZHANG Fangliang, Ms. WANG Ye, and Mr. MENG Jiange; our non-executive Directors are Dr. WANG Luquan and Mr. PAN Yuexin; and our independent non-executive Directors are Mr. GUO Hongxin, Mr. DAI Zumian, and Ms. ZHANG Min.*

\* *For identification purposes only*